Image source: Pixabay

Highlights

  • Clinuvel is a global specialty pharmaceutical company focused on development of SCENESSE® drug
  • The coampny is focused on expanding its business in the Middle East, Europe and North America
  • Wolgen (Philippe Jacques) has the highest stake in the firm with a shareholding of nearly 6.83%

Clinuvel Pharmaceuticals Limited (ASX: CUV) is an ASX-listed international specialty pharmaceutical company which is engaged in commercializing and developing treatments for patients suffering from genetic, metabolic, systemic, and life-threatening, acute disorders. The company also offers healthcare solutions to general public. The lead therapy of CUV is SCENESSE® (afamelanotide 16mg), a first-in-class photoprotective and repigmentation drug.

In the financial year 2023, the company witnessed growth in cash, revenue and profitability marking the seventh year of consecutive growth. During the reported period, the company maintained the commercial distribution of SCENESSE, advanced clinical campaigns and expanded its melanocortin drug portfolio.

During FY23, the company recorded a 24.1% YoY growth in total revenues to AUD 83 million and a 47.1% YoY surge in net profit after tax to AUD 30.6 million. The revenue growth was backed by increased demand for SCENESSE®. 

Here’s the historical financial trend of CUV:

Top 10 shareholders of CUV

The top 10 shareholders of CUV have around 28.02% shareholding in the company. Wolgen (Philippe Jacques) and Ender 1, L.L.C., have the maximum stake in the firm with a shareholding of around 6.83% and 5.17%, respectively.

Recent business update

On 14 December 2023, the company released a chair elect letter. According to the update, Jeffrey Rosenfeld, CUV Chair, shared communication and broad strategy through a letter. Through the letter, he shared a brief about his role, which comprises strategic decision making for the benefits of shareholders, guiding board and committee function, and overseeing executive management.

The company informed that it plans to expand its business in the Middle East, Europe and North America, backed by its cash position of AUD 156.8 million at 30 June 2023.

Outlook

The company is committed to continuing its strategy to convert its technology to the advantage of patients and general public who are at high risk of DNA change. The company is advancing its aim to become a sustainable, diversified and integrated pharmaceutical firm.

Moreover, the company is focused on advancing pharmaceuticals, increasing in-house manufacturing and OTC product development, and tapping acquisition opportunities.

Share performance of CUV

CUV shares closed 0.81% up at AUD 16.27 apiece on 10 January 2024. Including this gain, it has dropped by 31.06% in the past one year and has surged by 2.46% in the past three months.

52-week high of CUV is AUD 28.72, recorded on 30 January 2023, while 52-week low is AUD 13.97, recorded on 4 October 2023.

 

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, and currency, is 10 January 2024. The reference data in this report has been partly sourced from REFINITIV.